Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy

BACKGROUND: GLV-1h68 is an attenuated recombinant vaccinia virus (VACV) that selectively colonizes established human xenografts inducing their complete regression. RESULTS: Here, we explored xenograft/VACV/host interactions in vivo adopting organism-specific expression arrays and tumor cell/VACV in...

Descripción completa

Detalles Bibliográficos
Autores principales: Worschech, Andrea, Chen, Nanhai, Yu, Yong A, Zhang, Qian, Pos, Zoltan, Weibel, Stephanie, Raab, Viktoria, Sabatino, Marianna, Monaco, Alessandro, Liu, Hui, Monsurró, Vladia, Buller, R Mark, Stroncek, David F, Wang, Ena, Szalay, Aladar A, Marincola, Francesco M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713268/
https://www.ncbi.nlm.nih.gov/pubmed/19583830
http://dx.doi.org/10.1186/1471-2164-10-301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713268/
https://www.ncbi.nlm.nih.gov/pubmed/19583830
http://dx.doi.org/10.1186/1471-2164-10-301

Ejemplares similares